Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go?

Pawel Muranski, Andrea Boni, Claudia Wrzesinski, Deborah E. Citrin, Steven A. Rosenberg, Richard Childs, Nicholas P. Restifo

Research output: Contribution to journalReview articlepeer-review

Abstract

In a recent clinical trial involving patients with metastatic melanoma, immunosuppressive conditioning with fludarabine and cyclophosphamide resulted in a 50% response rate in robust long-term persistence of adoptively transferred T cells. Experimental findings indicate that lymphodepletion prior to adoptive transfer of tumor-specific T lymphocytes plays a key role in enhancing treatment efficacy by eliminating regulatory T cells and competing elements of the immune system ('cytokine sinks'). Newly emerging animal data suggest that more profound lymphoablative conditioning with autologous hematopoetic stem-cell rescue might further enhance treatment results. Here we review recent advances in adoptive immunotherapy of solid tumors and discuss the rationale for lymphodepleting conditioning. We also address safety issues associated with translating experimental animal results of total lymphoid ablation into clinical practice.

Original languageEnglish (US)
Pages (from-to)668-681
Number of pages14
JournalNature Clinical Practice Oncology
Volume3
Issue number12
DOIs
StatePublished - Dec 2006

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go?'. Together they form a unique fingerprint.

Cite this